HAVN LIFE SCIENCES GRANTED SECTION 56 EXEMPTION TO BEGIN SCIENTIFIC WORK WITH PSILOCYBIN

Havn Life will develop methods for safe, standardized, quality- controlled production of medical compounds extracted from the Psilocybe spp. mushroom


September 10, 2020

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that, on August 31, 2020, its wholly-owned subsidiary, HAVN Research Inc., was granted a Section 56 exemption by Health Canada, pursuant to which it now has the ability to possess certain amounts of pure psilocybin for scientific purposes, specifically for the research and development of quality control methods.

Havn Life intends to immediately begin work on experiments with the objective of developing a set of methods for the safe, standardized, quality-controlled production of medical compounds extracted from the Psilocybe spp. mushroom.

“We are thrilled to be among the first to receive permission from the Canadian government to begin work with psilocybin”, stated Tim Moore, Co-CEO of Havn Life. “This important milestone will enable Havn to begin working toward creating method-validation and analytical chemistry to standardize methods for quality control and testing of these substances.”

“Having access to compounds is essential in order to further research in the medical field. This is the start of our journey into developing standardized protocols to ensure that as this industry grows, we understand efficient new methodology”, stated Susan Chapelle, Havn Life Co-CEO, noting the advent of new technology and variables in extraction have changed significantly in the last decade.

The Company also announces that it has granted an aggregate of 2,135,000 stock options and 500,000 Restricted Share Units under its share-based compensation plan (the “Plan”). The stock options are exercisable at a price of $0.65 CDN for a period of 5 years, and the stock options and Restricted Share Units are subject to the terms of the Plan. The Company also issued 200,000 common shares in respect of a debt settlement.

On Behalf of The Board of Directors
Susan Chapelle & Tim Moore
Co-CEOs


About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on FacebookTwitter and Instagram.

Connect

Investor Relations
ir@havnlife.com
604 (359)-0060

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life

Media Contact
Brittany@exvera.com
778-238-6096

HAVN LIFE SCIENCES GRANTED SECTION 56 EXEMPTION TO BEGIN SCIENTIFIC WORK WITH PSILOCYBIN

Havn Life will develop methods for safe, standardized, quality- controlled production of medical compounds extracted from the Psilocybe spp. mushroom


September 10, 2020

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that, on August 31, 2020, its wholly-owned subsidiary, HAVN Research Inc., was granted a Section 56 exemption by Health Canada, pursuant to which it now has the ability to possess certain amounts of pure psilocybin for scientific purposes, specifically for the research and development of quality control methods.

Havn Life intends to immediately begin work on experiments with the objective of developing a set of methods for the safe, standardized, quality-controlled production of medical compounds extracted from the Psilocybe spp. mushroom.

“We are thrilled to be among the first to receive permission from the Canadian government to begin work with psilocybin”, stated Tim Moore, Co-CEO of Havn Life. “This important milestone will enable Havn to begin working toward creating method-validation and analytical chemistry to standardize methods for quality control and testing of these substances.”

“Having access to compounds is essential in order to further research in the medical field. This is the start of our journey into developing standardized protocols to ensure that as this industry grows, we understand efficient new methodology”, stated Susan Chapelle, Havn Life Co-CEO, noting the advent of new technology and variables in extraction have changed significantly in the last decade.

The Company also announces that it has granted an aggregate of 2,135,000 stock options and 500,000 Restricted Share Units under its share-based compensation plan (the “Plan”). The stock options are exercisable at a price of $0.65 CDN for a period of 5 years, and the stock options and Restricted Share Units are subject to the terms of the Plan. The Company also issued 200,000 common shares in respect of a debt settlement.

On Behalf of The Board of Directors
Susan Chapelle & Tim Moore
Co-CEOs


About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on FacebookTwitter and Instagram.

Connect

Investor Relations
ir@havnlife.com
604 (359)-0060

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life

Media Contact
Brittany@exvera.com
778-238-6096

BETTER PLANT READY FOR U.S. SALES OF ITS FDA LISTED GEL-BASED HAND SANITIZER

Vancouver, B.C. – September 10, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that subsidiary Urban Juve has completed manufacturing of its hand sanitizer gel and is launching the product in both Canada and the U.S. The hand sanitizer gel is listed with the FDA (NDC 75385-0010-1) and has received Natural health Product Number 80098154 from Health Canada. Urban Juve’s Ultra Hydrating Hand Sanitizer Spray received Health Canada approval on March 27, 2020 (NPN 80097926) and is for sale on Amazon.ca and Canadian retail stores including select Pharmasave stores. The newly listed hand sanitizer gel is now for sale on urbanjuve.com in both Canada and the US, with free shipping on orders of $50 or more.

“The gel is formulated with 65% ethyl alcohol which helps kill germs, while aloe vera and eucalyptus essential oil protect the skin.” says Amber Allen, VP of Sales for Better Plant. “We believe there is an opportunity in the marketplace for high quality hand sanitizers at a reasonable price, with essential oils that provide health benefits. It is exciting that we are now FDA listed and can start shipping this fantastic product to the USA.”

According to researchandmarkets.com, the market for hand sanitizer across the globe is expected to rise over 600% during 2020, fueled by preventative recommendations by the World Health Organization and driven by the ability of alcohol-based sanitizers to prevent infections and kill bacteria, fungi, and viruses.

One of the most common complaints with hand sanitizers are that the alcohol can cause the skin to dry out and sometimes even crack. “In order to create a truly moisturizing, nourishing and luxurious product, we have blended aloe vera extract for skin hydration, witch hazel for its anti-inflammatory and antiviral properties, and essential oils to protect the skin,” says Bhavna Solecki Director of Research and Product Development. “One of the unique selling points of our hand sanitizer is that it is formulated specifically to hydrate the skin and protect it from harmful germs.”

The hand sanitizer market is expected to grow at a CAGR of over 17 per cent between 2019 and 2025 according to a report from Aritzon, with sales expected to reach USD $11-billion in 2020, a 600-per-cent increase over last year.

 

About Better Plant Sciences Inc. 

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It has 14 patent applications to protect its Intellectual Property, and over 200 proprietary wellness formulas at various stages of commercialization, including over 20 proprietary products that are now for sale via eCommerce or brick-and-mortar retail stores. It operates websites and oversees eCommerce and Amazon sales for over 200 JUSU plant based products for body, baby and home. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents.

 

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Kevan Matheson, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

HAVN LIFE SCIENCES ANNOUNCES COMPLETION OF ACQUISITION TRANSACTION

Vancouver, BC – Havn Life Sciences Inc. (the “Company” or “Havn Life”), is pleased to announce that it has successfully completed its acquisition of HAVN Research Inc. (“HAVN Research”), acquiring 100% of the outstanding shares of HAVN Research (the “Acquisition Transaction”).  HAVN Research is a biotechnology company engaged in the business of the research and development of psychopharmacological products, including the formulation of standardized psychoactive compounds derived from fungi.

Following completion of the Acquisition Transaction, the Company has 66,771,000 common shares in the capital of the Company issued and outstanding (the “Common Shares”). The Common Shares will be listed and posted on the Canadian Securities Exchange (the “CSE”), and are anticipated to commence trading at market open on September 8, 2020 under the stock symbol “HAVN”.

On Behalf of The Board of Directors
Susan Chapelle & Tim Moore
Co-CEOs


About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Havn Life’s research facility, Havn Labs, is located on the South Campus at The University of British Columbia (UBC). Learn more at: havnlife.com and follow us on FacebookTwitter and Instagram.

Connect

Investor Relations
ir@havnlife.com
604 (359)-0060

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life

Media Contact
Brittany@exvera.com
778-238-6096

 

Forward-Looking Statements CautionThis news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking, including all statements in regard to the future plans or prospects of HAVN Research or the Company. The Company does not assume any obligation to update any forward-looking statements except as required under the applicable laws.

The CSE has not reviewed, approved or disapproved the content of this press release

HAVN LIFE SCIENCES INC. ANNOUNCES LAUNCH & FILING OF PRELIMINARY PROSPECTUS

Havn Life Sciences Inc. is focused on the standardized, quality-controlled extraction of psychoactive compounds including psilocybin from plants and fungi, and the development of natural health care products from novel compounds.


June 25, 2020

Vancouver, BC – Havn Life Sciences Inc. (the “Company” or “Havn Life”), announces launch and filing of its preliminary prospectus. Havn Life is a biotechnology company on a mission to unlock human performance using evidence-informed research. The Company is aimed at improving cognitive performance through the standardized extraction of psychoactive compounds and the development of natural health care products from novel compounds.

“In order for researchers to fully understand the therapeutic potential of psilocybin and how it can be utilized to treat disease and mental conditions, methods must be developed to ensure that researchers have access to safe, standardized, quality-controlled derivatives and formulations,” says Havn Life Co-CEO Susan Chapelle, a former civic politician and recognized thought leader in the Canadian cannabis space who has consulted with senior levels of government, and brings 25 years of leadership experience in the health, non-profit, and private sectors in Canada.

Havn Life has a dedicated research facility (Havn Labs) located in the South Campus of The University of British Columbia (UBC). Through its team of scientists with extensive experience in chemistry and formulation development, Havn Life is standardizing the extraction of psychedelic compounds to support the development of innovative therapies addressing human health.

“At present, the supply in the illicit psychedelic market is primarily provided by small scale growers, about which there is little information available. Scaling agriculture methods is difficult and without foundational methods for growing this genus of mushrooms, it is unknown if these species can be grown at scale. To date, there are no standardized or quality control methods that have been developed for investigators. The standardized methodology is essential for growing, extracting, and synthesizing these compounds.” added Chapelle. “And that is where Havn Life comes in.”

Vic Neufeld, who previously served as CEO of Aphria for five years during its large scale build up to become one of the leading cannabis producers in the world, and serves as a director of Havn Life said: “Canada is uniquely positioned to decriminalize several psychedelic substances through its constitutional framework. The psychedelic industry is poised to disrupt the current pharmaceutical industry and shift the mental health and well-being market towards novel plant-based products. And for this to happen, the market will require these standardized, quality-controlled substances.”

Neufeld also served as CEO of Jamieson Laboratories, Canada’s largest manufacturer and distributor of natural vitamins, minerals, concentrated food supplements, herbs and botanical medicines. Under his leadership, Jamieson grew its market share from 7 to 27 per cent, and sales grew from $20 million annually to over $250 million.

Havn Life’s multi-disciplinary team includes Co-CEO Tim Moore, who has championed start-ups, acquisitions and has over 30 years’ experience in Fortune 500 leadership roles in Canada and USA. He was former CEO of Green Growth Brands, a US multi-state cannabis operator, which also operated over 200 mall-based CBD kiosks and rose from IPO to a peak valuation of over 1.2 billion dollars. Moore is the former President of The Clorox Company of Canada and COO of Synnex Canada.

Dr. Ivan Casselman (Ph.D., FLS) serves as Havn Life’s Chief Psychedelic Officer. Dr. Casselman is an experienced formulation chemist with a strong foundation in nutraceutical formulation and product development. One of the key components to his research has been a focus on ethnography, experiential investigation, and ensuring a comprehensive understanding of the human psychedelic interface.

Alexzander Samuelsson (BSc) serves as Havn Life’s Chief Research Officer. Mr. Samuelsson has developed patented processes in the extraction as well as formulations and product development within the cannabis industry. His experience and focus on extraction, separation, and isolation of novel compounds within plants and fungi to create natural health products will greatly benefit Havn Life in achieving its strategic goals.

On Behalf
Susan Chapelle & Tim Moore
Co-CEOs


About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human performance using evidence-informed research. The company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from novel compounds. Havn Life’s research facility, Havn Labs, is located in the South Campus at The University of British Columbia (UBC).

Connect

Investor Relations
ir@havnlife.com
604 (359)-0060

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life

Media Contact
Brittany@exvera.com
778-238-6096

HAVN LIFE SCIENCES INC. ANNOUNCES APPOINTMENT OF GARY LEONG AS CHIEF SCIENCE OFFICER

Gary Leong has over 30 years’ experience in the Pharmaceutical and Natural Health Products Industry.  


July 6, 2020

Vancouver, BC – Havn Life Sciences Inc. (the “Company” or “Havn Life”), announces the appointment of Gary Leong as Chief Science Officer of Havn Life. Mr. Leong has over thirty (30) years of experience in the Pharmaceutical and Natural Health Products (“NHP”) industry.

Mr. Leong was the Chief Scientific Officer at Aphria Inc. in Leamington, ON from its inception in 2014 to 2019. At Aphria, Gary established and oversaw the Quality Assurance, Quality Control, Regulatory Affairs and Research and Development functions. Prior to this, Gary served as the Chief Scientific Officer Jamieson Laboratories in Windsor, ON for fourteen (14) years. He has managed the scientific and quality function for Boehringer Ingelheim, Natural Factors Nutritional Products Ltd. and Nordion. Gary holds a B.Sc. in Chemistry and a M.B.A. in Quality Management. Gary has served on the Board of Directors of several public companies and research societies as well as an advisor to several Canadian government regulatory advisory committees.

Mr. Leong will work with the team at Havn Life to develop formulations for Havn Life’s Retail division which will look to bring NHP products that include novel psychoactive compounds to health food stores across the country. In addition, he will also work with the Havn Lab’s team to develop and plan research studies relating to the potential health benefits of psilocybin and other psychoactive compounds.

Havn Life’s Co-CEO, Susan Chapelle stated, “Mr. Leong has a long track record of developing products and formulations for the NHP industry as well as being involved in research. His experience makes him an incredible asset for the Havn Team, and we look forward to building both the Retail and Labs divisions of Havn with his capabilities.”

On Behalf
Susan Chapelle & Tim Moore
Co-CEOs


About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human performance using evidence-informed research. The company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from novel compounds. Havn Life’s research facility, Havn Labs, is located in the South Campus at The University of British Columbia (UBC).

Connect

Investor Relations
ir@havnlife.com
604 (359)-0060

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life

Media Contact
Brittany@exvera.com
778-238-6096

BETTER PLANT SCIENCES SUBMITS APPLICATION FOR AYURVEDIC SKIN OINTMENT TO COMBAT INFECTIOUS DISEASE

August 25,  2020 – Vancouver, BC: Better Plant Sciences Inc. (CSE:PLNT) (OTCQB:BOSQF) (FE:YG3) (“Better”) subsidiary Urban Juve Provisions Inc. (“Urban Juve”) announces that it has conducted research and development into plant-based topical products that fight against or prevent infectious diseases leading to the submission of a Natural Health Product (“NHP”) application for a plant-based, antiseptic skin ointment to Health Canada to obtain an NHP number for the product.

 

“This plant-based skin ointment was developed using the principles of Ayurveda. We have spent the last six months working to identify the plants with the most active compounds with antibacterial and antiviral properties,” says Bhavna Solecki, Director of Research and Product Development at Better Plant Sciences. “We are very pleased with the resulting plant-based antiseptic skin repair and healing ointment formula we have developed to be used to help heal minor skin wounds, cuts, burns, and bruises.”

 

According to the Natural Health Products Regulations, compendial product license applications such as this are processed within 60-days of receipt.

 

GM Insights reported that the global wound care biologics market was worth US$ 1.40 Billion in 2018 and is expected to reach a value of US$ 2.5 billion by 2025 with a CAGR of around 9%. Wound care biologics refer to drugs extracted or semi-synthesized from natural sources which are used for controlling and healing infections.

 

The Better Plant Sciences research and development team focused on using polyherbal combinations, which use a group of plants to achieve an effective therapeutic effect. In Ayurveda, most classical preparations are polyherbal, involving a combination of 3 to 30 plants that are combined in precise ratios to achieve the desired result.

 

“During the compounding process, one or two of the plants will be active and the others play a supporting role. The supporting herbs have different therapeutic values calculated for different purposes, which act as catalysts to help proper absorption, transportation, and to reduce toxicity,” added Solecki.  “We use spices because the phytochemicals within spices are secondary metabolites, which serve to protect against damage by insects, animals, fungi, pathogens, and parasites.”

 

About Better Plant Sciences Inc.

Better develops and acquires intellectual property and other assets related to plant-based products and therapeutics, and develops, manufactures, markets, sells and distributes plant-based products that improve lives. It has 14 patent applications to protect its formulas and over 200 proprietary wellness formulas at various stages of commercialization, including over 20 products that are now for sale via e-commerce or brick and mortar retail stores. It has signed an agreement to acquire JUSU branded plant-based assets from JUSU Bar, JUSU Body and JUSU Cbd, and expects to complete the acquisition this fall. The acquisition includes all inventory, packaging, raw ingredients, and intellectual property related to 300 plant-based products as well as the e-commerce sites where those products are sold. Its majority-owned subsidiary NeonMind Biosciences Inc. is engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and is developing a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms.

 

Investor Relations Contact:

Kevan Matheson, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEONMIND READY TO LAUNCH FOUR MUSHROOM COFFEE BLENDS

August 20,  2020 – Vancouver, BC: Better Plant Sciences Inc. (CSE:PLNT) (OTCQB:BOSQF) (FE:YG3) (“Better Plant”) announces that subsidiary NeonMind Biosciences (“NeonMind”) has completed final product development for four unique Ayurveda-inspired and botanical-enhanced mushroom coffee blends which are now moving into the mixing stage with a co-packer.

The coffees are fair trade and organic, with Ayurvedic organic botanicals and organic mushroom extracts. Each is formulated with adaptogenic, immune-boosting medicinal mushrooms that are antioxidant and nutrient-rich. The formulas contain special blends of reishi, cordyceps, lion’s mane and turkey tail mushrooms, all of which are widely regarded for their health benefits.

“Four unique blends will be available: two instant mushroom coffee blends and two roasted coffee blends. Functional mushrooms are booming in popularity as a supplement to boost immunity and brain function,” said Penny White, CEO of Better Plant.

According to Data Bridge Market Research, the global medicinal mushroom market is expected to reach US$78.7 billion by 2025, from US$38.1 billion in 2017 growing at a CAGR of 9.5% during the forecast period of 2018 to 2025.

“We worked directly with Ayurveda botanical companies in India that are fair trade to source the highest quality ingredients,” said Bhavna Solecki, Director of Research and Product Development at Better Plant. “Fair trade is important to us because we want to support producers in developing countries and contribute to building sustainable communities.”

The coffees will contain Ayurvedic botanical ingredients such as holy basil, which naturally decreases anxiety; moringa, which acts as an antiviral and antidepressant; gotu kola, which reduces anxiety and stress while improving circulation, and amla; a potent fighter against bacteria and viruses.

All four blends have been sent to a third-party lab for nutritional facts testing as per Health Canada regulations for functional foods. This will test for things such as: moisture, nutrition labeling, fat and fat composition, protein, carbohydrate, cholesterol, sugar, dietary fiber, iron, calcium, sodium, potassium, ash content, and energy.

NeonMind has completed the box and packaging design for the coffees, and has sourced environmentally friendly packaging for the products. NeonMind has commenced development of a website with full e-commerce capabilities, which it intends to launch in tandem with its expected initial product launch in October 2020. The website will be powered by Shopify, which will allow for an optimized user experience across all devices and encourage sales conversions.

 

About Better Plant Sciences Inc.

Better Plant Sciences develops and acquires intellectual property and other assets related to plant-based products and therapeutics, and develops, manufactures, markets, sells and distributes plant-based products that improve lives. It has over 200 proprietary wellness formulas at various stages of commercialization, including over 20 products that are now for sale through  e-commerce or brick and mortar retail stores. It also has signed an agreement to buy JUSU bar and JUSU body products and business and expects to complete the acquisition this fall, adding active websites with over 200 products for sale, and another 100 formulas to its assets.  It has 14 patent applications to protect its formulas.  Its majority-owned subsidiary NeonMind Biosciences Inc. is engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and is developing a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms.

 

Investor Relations Contact:

Kevan Matheson, Investor Relations

invest@betterplantsciences.com 

1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Why Are Psychedelics And Mining Companies Merging In Canada?

Why Are Psychedelics And Mining Companies Merging In Canada?

Since the first psychedelic companies went public in March, an array of other psychedelic start-ups followed along in a trend that can now be safely referred to as the “Psychedelic Rush.”

In the last two months, at least five different psychedelics companies announced plans to go public in Canada, including Cybin Corp.Entheon BiomedicalNovamind VenturesSilo Wellness and Havn Life Sciences.

With the exception of Havn, each chose to go public by way of reverse take-overs with companies from the mining sector.

As was the case with the boom of cannabis in 2013, mining companies driving the junior capital markets in Canada have laid the grounds for the development of high-risk venture industries.

Today, psychedelics are taking the lead.

Psychedelics, Reverse Acquisitions And… Mining?

What seems like an unusual combination of industries is actually a run-on-the-mill event for Canadian capital markets.


Thousands of traders are getting a 90% win-rate trading options! Click Here to See How!


Richard Carleton, CEO of the Canadian Stock Exchange, explained that the Canadian small-cap space has been largely focused on early-stage mining exploration, including oil and gas.

These companies have two possible outcomes. They either find something worth drilling and raise additional capital to develop a mine, or they don’t find anything.

“And so you have basically a group of companies that have raised some money, explored a property, didn’t succeed and now the management team and the shareholders are looking for another opportunity,” Carleton said.

That’s where psychedelics come in. These companies are trying to raise money quickly, and going public through a reverse acquisition is one of the fastest ways to do it.

In a reverse takeover (RTO), a private company looking to go public will merge with a public company in order to bypass the lengthy and expensive process of an initial public offering.

Alan Friedman, Principal at Bayline Capital Partners adds that the mining companies are available, but they’re not mining companies anymore.

“Once upon a time they were mining operating companies. Today, they’re defunct. They’re just sitting there listed on the stock exchange. And they’re good vehicles to reverse other assets into.”

For Friedman, the mining sector has “hot” cycles that last about seven years.

In 2013, one of these cycles came to an end. That moment happened to coincide with the cannabis boom. Cannabis companies were looking for ways to go public and the mining, oil and gas sector had left the perfect riverbed for a high-risk, junior capital investment market.

The same thing is happening with psychedelics.

“When you see psychedelics come along in 2020, it’s the new hot, trendy business. They can raise money, but they have to go public quick,” says Friedman. “Because a lot of the money that comes in is based on the fact they go public, because those investors like to see liquidity.”

Going Public in Canada: IPOs Vs. RTOs

According to Friedman, the quickest way for a company to go public is by way of a reverse takeover, because the vehicle and the shareholders are already there.

“80% of the companies in Canada go public by way of a reverse takeover,” Carleton said. “So it’s a very well-traveled path.”

It’s also less expensive.

“It could be a good few hundred thousand bucks cheaper,” Friedman added. “And it could be a few months quicker.”

Friedman is currently working with a private psychedelics company called Mind Health, which is in the process of negotiating a reverse takeover, and plans to go public in three months.

RTOs, however, also come with their fair share of challenges.

“When you’re switching industries, the shareholders are not in any way necessarily interested in that story or in that sector. And what can happen in a number of instances is that at the first sign of any kind of buying interest, once the company has gone public, those shareholders tend to sell so that it’s almost like there’s a built-in overhang in the company’s cap table,” Carleton explained.

As a result, when the company goes public, it’s harder to see the same kind of exuberant price moves seen when companies that go public by way of an IPO.

Also, with an RTO, the new company inherits all of the liabilities associated with the former company. And of course, in the case of mining companies, there may well be environmental issues, says Carleton.

It’s crucial to do due diligence and proper research an RTO partner before committing to a deal, Friedman advised. Although — in every case — there’s risk.

Nonetheless, RTOs are the preferred method of going public for small-cap companies in the junior markets/IPOs are reserved for larger, more established players who typically go after senior equity markets.

What To Look For In An RTO Partner?

Cybin CEO Paul Glavine is currently in the process of doing a reverse takeover with a mining company called Clarmin Explorations.

Cybin achieved full support from over 60% of Clarmin’s existing shareholders, Glavine said in an email. In this case, Clarmin’s management team will step out to let Cybin’s team on the helm.

Other psychedelics companies, like Entheon Biomedical — which merged with mining company MPV Exploration — looked for added value in their partner company. CEO Timothy Ko said MPV provided more than just a means to trade their stock on the open market.

“There was no shortage of interested, I guess, ‘shell’ partners. I think Canada has a plentitude of those opportunities available. But ultimately, it was a process of discernment where we had to say, ‘okay, the nature of the investor and the management on the other side, do they have a strategic value to us?'” says Ko.

Entheon found that MPV’s investors could add value to the company by bringing in their shared experiences in biotech, pharma and healthcare, and the management team could offer its experience raising money in the public markets.

Picture based on photos by Photo by Dominik Vanyi and Егор Камелев on Unsplash.